Free Trial

Oscar Health, Inc. (NYSE:OSCR) Receives $16.58 Consensus Target Price from Brokerages

Oscar Health logo with Finance background

Oscar Health, Inc. (NYSE:OSCR - Get Free Report) has earned an average recommendation of "Reduce" from the seven analysts that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $16.58.

A number of brokerages have weighed in on OSCR. Piper Sandler decreased their target price on shares of Oscar Health from $25.00 to $18.00 and set an "overweight" rating for the company in a research note on Monday, June 9th. Barclays assumed coverage on shares of Oscar Health in a report on Wednesday. They issued an "underweight" rating and a $17.00 target price for the company. Wells Fargo & Company downgraded shares of Oscar Health from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $20.00 to $16.00 in a report on Thursday, March 13th. Raymond James Financial downgraded shares of Oscar Health from an "outperform" rating to a "market perform" rating in a report on Tuesday, June 24th. Finally, Wall Street Zen downgraded shares of Oscar Health from a "buy" rating to a "hold" rating in a report on Sunday, June 8th.

Get Our Latest Research Report on OSCR

Insider Activity at Oscar Health

In other Oscar Health news, Director Elbert O. Jr. Robinson sold 25,000 shares of the stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $16.43, for a total transaction of $410,750.00. Following the completion of the transaction, the director owned 64,512 shares of the company's stock, valued at $1,059,932.16. This represents a 27.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 24.39% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Oscar Health by 3.7% during the 1st quarter. Vanguard Group Inc. now owns 19,698,442 shares of the company's stock valued at $258,247,000 after buying an additional 700,469 shares in the last quarter. Deerfield Management Company L.P. Series C raised its position in shares of Oscar Health by 50.7% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 11,835,000 shares of the company's stock valued at $159,062,000 after buying an additional 3,983,325 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Oscar Health by 4.1% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 11,826,245 shares of the company's stock valued at $155,043,000 after buying an additional 467,301 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Oscar Health by 348.7% during the 4th quarter. JPMorgan Chase & Co. now owns 10,360,529 shares of the company's stock valued at $139,246,000 after buying an additional 8,051,379 shares in the last quarter. Finally, Thrive Capital Management LLC raised its position in shares of Oscar Health by 33.4% during the 4th quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company's stock valued at $85,258,000 after buying an additional 1,588,395 shares in the last quarter. Institutional investors own 75.70% of the company's stock.

Oscar Health Stock Down 0.6%

NYSE OSCR traded down $0.10 during mid-day trading on Friday, reaching $16.52. The stock had a trading volume of 29,008,142 shares, compared to its average volume of 6,275,183. Oscar Health has a 1 year low of $11.20 and a 1 year high of $23.79. The stock has a market cap of $4.21 billion, a PE ratio of 59.00 and a beta of 1.90. The company has a fifty day moving average price of $16.02 and a 200 day moving average price of $14.81. The company has a debt-to-equity ratio of 0.22, a current ratio of 0.88 and a quick ratio of 0.88.

Oscar Health (NYSE:OSCR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.83 by $0.09. The business had revenue of $3 billion during the quarter, compared to analyst estimates of $2.87 billion. Oscar Health had a net margin of 1.22% and a return on equity of 10.59%. The company's quarterly revenue was up 42.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.62 EPS. On average, research analysts expect that Oscar Health will post 0.69 earnings per share for the current year.

Oscar Health Company Profile

(Get Free Report

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.

Recommended Stories

Analyst Recommendations for Oscar Health (NYSE:OSCR)

Should You Invest $1,000 in Oscar Health Right Now?

Before you consider Oscar Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oscar Health wasn't on the list.

While Oscar Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines